Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ans – page 12

1 400 clinical trials in Ans, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ans at a glance
1 400
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 400 trials in Ans

Open in trial search

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Delpacibart zotadirsen
  • Sponsor:Avidity Biosciences Inc.

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Incyte Corp.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Patients with Clinical Stage II-III Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Endometriosis

Recruiting

Letrozole During IVF/ICSI for Women with Endometriosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Letrozole
  • Sponsor:UZ Brussel

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ans

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. The research explores innovative approaches to manage functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Acid Reflux Treatment

This primary care study evaluates different therapeutic approaches, including on-demand medication use and alternative treatment formulations, to improve patient outcomes in digestive health management.

02 Primary Care Innovation

Groundbreaking research in medication management strategies, specifically targeting long-term PPI use in primary care settings. The study compares various approaches to reduce unnecessary medication dependency.

  • Medication De-prescribing
  • Patient-Centered Care
  • Treatment Optimization

The research aims to establish more effective protocols for managing common digestive conditions while minimizing long-term medication use.

03 Therapeutic Alternatives

Investigation into alternative treatment options for managing heartburn and related gastrointestinal conditions. The study explores the effectiveness of different therapeutic approaches.

  • Alternative Treatments
  • Symptom Management
  • Treatment Comparison

This research evaluates the comparative effectiveness of various treatment strategies, including alginate formulations and flexible dosing schedules.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.